Showing 1 - 7 results of 7 for search 'Andreas Pinter', query time: 0.01s
Refine Results
-
1
-
2
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants... by Kristian Reich, Kilian Eyerich, Knut Schäkel, Peter Weisenseel, Andreas Pinter, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut
Published 2021-09-01Get full text
Article -
3
High content imaging shows distinct macrophage and dendritic cell phenotypes for psoriasis and atopic dermatitis by Nathalie J. Behr, Sandra Pierre, Tanja Ickelsheimer, Nicole Ziegler, Sonja Luckhardt, Aimo Kannt, Andreas Pinter, Gerd Geisslinger, Stephan M. G. Schäfer, Anke König, Klaus Scholich
Published 2025-05-01Get full text
Article -
4
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial by Robert Bissonnette, Ronald Vender, Andreas Pinter, Leanne M. Stanley, Carrie R. Houts, Megan Miller, Amy M. DeLozier, Shu Li, Charles Iaconangelo, Laura K. Ferris
Published 2025-12-01Get full text
Article -
5
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison by Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian
Published 2025-07-01Get full text
Article -
6
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Stud... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Published 2024-11-01Get full text
Article -
7
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Published 2025-01-01Get full text
Article